SYRE
Spyre Therapeutics, Inc.32.97
-0.37-1.11%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
2.56BP/E (TTM)
-Basic EPS (TTM)
-1.32Dividend Yield
0%Recent Filings
8-K
Spyre's $486M cash update
Spyre Therapeutics announced on October 14, 2025, preliminary cash, cash equivalents, and marketable securities of $486.2 million as of September 30, 2025, bolstering its runway amid biotech uncertainties. This unaudited figure, pending final closing, underscores financial stability yet highlights risks from macroeconomic pressures and geopolitical tensions. Cash position holds firm.
10-Q
Q2 FY2025 results
Spyre Therapeutics narrowed its Q2 FY2025 net loss to $36.7M from $38.8M y/y, thanks to a $10M gain from legacy asset milestones offsetting a 23% jump in R&D spend to $40.1M as clinical programs advance. Operating loss improved to $41.9M, with interest income steady at $5.9M; diluted EPS held at -$0.49 on 60.3M shares, reconciling to YTD -$1.09. Cash burn moderated to $87.6M YTD, leaving $526.6M in cash and marketable securities at quarter-end, bolstered by prior raises and no debt. The $10M pegzilarginase gain highlights smart legacy monetization. Yet regulatory hurdles in biotech trials loom large.
8-K
Positive TL1A data, trials advance
Spyre Therapeutics reported positive interim Phase 1 data for anti-TL1A antibodies SPY002 and SPY072, showing good tolerability and PK supporting quarterly or biannual dosing with full target engagement up to 20 weeks. The company launched the Phase 2 SKYLINE-UC trial in May 2025 for UC monotherapies and combinations, with SKYWAY-RD for rheumatic diseases set for Q3 initiation. Cash stood at $526.6 million as of June 30, 2025, funding operations into H2 2028. Pipeline advances nine proof-of-concept readouts by 2027.
8-K
Positive anti-TL1A Phase 1 results
Spyre Therapeutics unveiled positive interim Phase 1 results for SPY002 and SPY072, extended half-life anti-TL1A antibodies well-tolerated up to 1500 mg doses with no serious adverse events and a ~75-day half-life—over three times longer than first-generation rivals—enabling quarterly or biannual subcutaneous dosing while fully suppressing free TL1A for 20 weeks at the lowest dose. The company initiated its SKYLINE-UC Phase 2 platform trial in May 2025 for ulcerative colitis, incorporating SPY002 alongside other monotherapies and combinations, and announced the SKYWAY-RD basket trial for SPY072 in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis, set to start in Q3 2025. Nine proof-of-concept readouts are anticipated in 2026-2027. Final Phase 1 data may differ from these interim findings.
8-K
Spyre elects directors, approves comp
Spyre Therapeutics held its annual stockholder meeting on May 29, 2025, electing Peter Harwin, Michael Henderson, and Sandra Milligan as Class III directors until 2028, with Harwin and Milligan facing notable withheld votes. Stockholders approved executive compensation on an advisory basis and ratified KPMG LLP as auditors for 2025. The board refresh signals continuity amid biotech volatility.
AVTX
Avalo Therapeutics, Inc.
18.82+1.12
FNCH
Finch Therapeutics Group, Inc.
13.50+0.06
GYRE
Gyre Therapeutics, Inc.
7.58+0.04
KPRX
Kiora Pharmaceuticals, Inc.
2.04-0.02
KYMR
Kymera Therapeutics, Inc.
84.19-1.49
LYRA
Lyra Therapeutics, Inc.
3.86-0.07
SABS
SAB Biotherapeutics, Inc.
3.99-0.01
SPRC
SciSparc Ltd.
1.61-0.03
SPRO
Spero Therapeutics, Inc.
2.27-0.02
VYNE
VYNE Therapeutics Inc.
0.40+0.04